Martine Rothblatt, who serves as chairperson and chief executive officer of United Therapeutics (NASDAQ: UTHR), executed sales of common stock totaling roughly $5 million on March 24, 2026. Those sales were completed pursuant to a pre-established 10b5-1 trading plan and consisted of 5,891 shares sold at prices between $516.8363 and $536.02.
On the same date, Rothblatt also exercised stock options to acquire 9,500 shares of United Therapeutics common stock at an exercise price of $146.03 per share, for an aggregate value of $1,387,285.
United Therapeutics shares have been trading near their 52-week high of $548, representing a 68% gain over the past year. According to InvestingPro analysis cited by the company, the stock appears overvalued at current levels. The InvestingPro commentary highlights United Therapeutics' strong operating characteristics, including gross profit margins of 88% and a balance sheet holding more cash than debt, which are noted as two of 15 ProTips available to subscribers. Investors seeking more detailed metrics can consult UTHR’s Pro Research Report.
After completing the transactions on March 24, Rothblatt's direct ownership of United Therapeutics common stock stands at 40,513 shares. Indirect holdings attributed to Rothblatt include 166 shares held by a spouse and multiple trust holdings totaling 324,518; 258,117; 45,596; and 10,962 shares, respectively.
In separate corporate developments, United Therapeutics announced the publication of its phase 3 TETON-2 study results in the New England Journal of Medicine. The published study showed that nebulized Tyvaso significantly improved lung function in patients with idiopathic pulmonary fibrosis, meeting the trial's primary endpoint.
The company also unveiled a $2 billion stock repurchase program. The repurchase authorization includes an initial $1.5 billion accelerated share repurchase agreement with Citibank. The remaining $500 million of the program will be available for additional repurchases at the company’s discretion over the coming year.
Market analysts have reacted to the clinical and capital actions. TD Cowen interpreted the buyback and clinical progress as affirmations of confidence in United Therapeutics' franchise, maintaining a Buy rating and a $575 price target. Cantor Fitzgerald adjusted its valuation stance by raising its price target for United Therapeutics to $625 while keeping an Overweight rating.
These transactions and corporate announcements come as the company sits near its yearly high and amid differing views on valuation metrics, according to the InvestingPro analysis cited above.